Parexel Says It Is Ideally Positioned As Big Pharma Shakes Up R&D Efforts
This article was originally published in The Pink Sheet Daily
Executive Summary
Noting its recent five-year contract with Pfizer, the CRO predicts 13% revenue growth for fiscal 2012.